P-230 Pomalidomide, daratumumab, and dexamethasone after lenalidomide treatment in patients with relapsed or refractory multiple myeloma (RRMM): final overall survival analysis of the phase 2 MM-014 study

Saved in:
Bibliographic Details
Published in:Clinical lymphoma, myeloma and leukemia myeloma and leukemia, 2023-09, Vol.23, p.S162-S162
Main Authors: Bahlis, Nizar, Samaras, Christy, Reece, Donna, Sebag, Michael, Matous, Jeffrey, Berdeja, Jesus, Shustik, Jesse, Schiller, Gary, Ganguly, Siddhartha, Song, Kevin, Seet, Christopher, Acosta-Rivera, Mirelis, Quick, Donald, Anz, Bertrand, Fonseca, Gustavo, Liu, Hongjuan, Gentili, Christian, Siegel, David
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:2152-2650
2152-2669
DOI:10.1016/S2152-2650(23)01848-7